Follow us on our mission to transform
diseases with saRNA therapeutics.

Follow us on our mission to transform
diseases with saRNA therapeutics.

PRESS RELEASES

29 Sep, 2020

MiNA Therapeutics Appoints Peter Bains as Chief Business Officer

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business Officer (CBO), effective September 22, 2020. Mr Bains currently serves on MiNA’s Board of Directors as Non Executive Director and will retain this position while joining MiNA’s senior leadership team. With more than three decades of experience in the global pharmaceutical industry, he will leverage his years of expertise to lead the Company’s business development and corporate strategy activities […]

10 Sep, 2020

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund, with participation from existing investors. The proceeds from the financing will be used to advance MiNA’s pipeline of proprietary, first-in-class, small activating RNA (“saRNA”) therapeutics, and to support the continued clinical development of MiNA’s lead candidate, MTL-CEBPA, as a combination treatment in cancer. As part of the Series A financing, Dr. Gur Roshwalb, M.D., M.B.A., Managing Director at aMoon, has joined the Board of Directors at MiNA Therapeutics. MTS Securities, LLC acted as the exclusive placement agent in connection with the financing […]

29 May, 2020

MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today top line results from the Phase Ib dose escalation and cohort expansion study, OUTREACH, of lead candidate MTL-CEBPA in combination with sorafenib standard of care in patients with advanced hepatocellular carcinoma (HCC or liver cancer). The study met its primary endpoints of safety and tolerability for MTL CEBPA administered either concomitantly or sequentially with sorafenib. In addition, five patients experienced objective tumour responses, including two complete responses during the combination treatment […]

27 May, 2020

MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. It is the first publication in which a small activating RNA treatment (MTL-CEBPA) demonstrated clinical benefit. In addition, the Company provided an update on its ongoing clinical trials for lead program MTL-CEBPA and its drug discovery programs […]

03 March, 2020

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients […]

07 January, 2020

MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA (“saRNA”) molecules in metabolic diseases. The collaboration combines MiNA’s leading expertise in the discovery and development of saRNA therapeutics with AstraZeneca’s experience in identifying and bringing breakthrough treatments to patients with metabolic diseases […]

30 September, 2019

MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment

MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced final Phase 1 clinical data of MTL-CEBPA as a single agent in patients with advanced liver cancer as well as pre-clinical data demonstrating synergistic immunological and anti-tumour activity of MTL-CEBPA in combination with anti-PD1 checkpoint inhibition. The data will be presented in two posters at the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain on September 28th and September 30th […]

02 April, 2019

MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR

MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation. The data will be presented today in two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place in Atlanta, Georgia […]

19 December, 2018

MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today enrolment of the first patients treated with MTL-CEBPA in combination with Sorafenib in OUTREACH, the multi-centre Phase 1b clinical trial in patients with advanced liver cancer. The study is designed to assess the safety, tolerability and clinical activity of MTL-CEBPA in combination with Sorafenib. OUTREACH is currently being conducted at multiple clinical trials sites in the United Kingdom, Singapore and Taiwan […]

18 October, 2018

MiNA Therapeutics Announces Sosei Will Not Exercise Acquisition Option

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that Sosei Group Corporation (“Sosei”) has decided for strategic reasons not to exercise its option to acquire MiNA. The decision to relinquish these rights, which expire after October 18, 2018, is a result of Sosei’s strategic prioritisation. Sosei will retain their minority investment in MiNA Therapeutics based on their 2017 equity investment […]

19 September, 2018

MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference

MiNA Therapeutics, the pioneer in RNA activation therapeutics, provided yesterday an update from the ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer patients. The Chief Investigator of the trial reported observations of tumour responses in three patients when administered approved liver cancer therapies subsequent to treatment with MTL-CEBPA […]

04 June, 2018

MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients

MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer. In the study, MTL-CEBPA was generally well tolerated in patients with both healthy and impaired liver function and provided evidence of anti-tumour activity. MTL-CEBPA was […]

09 March, 2018

MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the publication of pre-clinical data on its MTL-CEBPA program in which the compound was shown to promote disease reversal in several models of liver disease and to reduce tumour burden in a model of liver cancer. MTL-CEBPA consists of CEBPA-51 small activating RNAs encapsulated in […]

08 November, 2017

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to […]

02 November, 2017

Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK

MiNA Therapeutics, the pioneer in RNA activation therapeutics, and LGC LINK, the oligonucleotide synthesis reagent manufacturer, and part of the Genomics division of LGC, today announced that Innovate UK has awarded the two companies a grant to develop liver targeted gene activation therapies for the treatment of liver diseases. The grant of up to approximately […]

06 September, 2017

MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the publication of new pre-clinical data supporting the on-target mechanism of action of drug candidate MTL-CEBPA. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform, consisting of CEBPA-51 small activating RNAs encapsulated in SMARTICLES® nanoparticles, and is currently being evaluated in […]

3 May, 2017

Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics

Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and MiNA Therapeutics Limited (“MiNA”) announced today that the companies have entered into a definitive agreement under which Sosei will make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company and pioneer in RNA activation therapeutics (small activating […]

14 November, 2016

MiNA Therapeutics Presents Data Demonstrating Survival Benefit of MTL-CEBPA in Animal Model of Liver Failure at AASLD Liver Meeting

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve survival in a rat model of liver failure. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a […]

27 September, 2016

Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of data supporting the on-target mechanism of action of drug candidate MTL-CEBPA. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a Phase I clinical study in patients with liver cancer. The data […]

17 March, 2016

MiNA Therapeutics Granted US Patent Covering Small Activating RNAs Targeting the CEBPA Gene

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has granted the first in a series of patents filed by MiNA Therapeutics protecting its CEBPA drug development program (US Patent Number 9,284,553). The patent covers the company’s lead program MTL-CEBPA, currently in preclinical development for […]

16 November, 2015

MiNA Therapeutics Announces AASLD Liver Meeting Presentation on Lead Program Demonstrating Reversal of Liver Failure in Animal Model

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve several markers of liver function in a rat model of liver failure. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and the company […]

13 October, 2015

David Blakey Ph.D. joins MiNA Therapeutics as Chief Scientific Officer

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the appointment of David Blakey Ph.D. as Chief Scientific Officer. Dr. Blakey will lead the Company’s research and development activities. “David brings to MiNA a depth of scientific expertise that will be critical in advancing our pipeline of innovative RNA-based therapies,” said Robert Habib, […]

18 December, 2014

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-based Therapeutics

Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA’s proprietary oligonucleotides and […]

18 November, 2014

MiNA Completes Exclusive License Agreement with University of California San Francisco

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF). The exclusive license complements MiNA’s fundamental intellectual property portfolio that broadly covers RNAa therapeutics, […]

20 December, 2013

Study published in Hepatology demonstrates ability of saRNA to improve liver function and inhibit carcinogenesis in vivo

MiNA Therapeutics, a biotechnology company developing RNA for transcriptional gene activation, announced today that its academic co-founders published a study in Hepatology demonstrating that saRNA therapeutics induced in vivo production of mRNA and proteins to improve liver function and inhibit tumour burden in a rat model of hepatocellular carcinoma (HCC). The research provides pre-clinical proof-of-concept […]

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close